



Italian Journal of Medicine

<https://www.italjmed.org/ijm>

eISSN 1877-9352

Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. The Early Access service lets users access peer-reviewed articles well before print/regular issue publication, significantly reducing the time it takes for critical findings to reach the research community.

These articles are searchable and citable by their DOI (Digital Object Identifier).

The **Italian Journal of Medicine** is, therefore, E-publishing PDF files of an early version of manuscripts that have undergone a regular peer review and have been accepted for publication, but have not been through the copyediting, typesetting, pagination, and proofreading processes, which may lead to differences between this version and the final one.

The final version of the manuscript will then appear in a regular issue of the journal.

The E-publishing of this PDF file has been approved by the authors.

Ital J Med 2025 [Online ahead of print]

Please cite this article as:

Di Micco P, Siniscalchi C. **How should we manage political instability in our standard of care? A global emerging issue around the world.** *Ital J Med* doi: 10.4081/itjm.2025.2371

Submitted: 11-10-2025

Accepted: 03-11-2025

 © the Author(s), 2025
Licensee PAGEPress, Italy

Note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

**How should we manage political instability in our standard of care?
A global emerging issue around the world**

Pierpaolo Di Micco,¹ Carmine Siniscalchi²

¹Internal Medicine Ward, “Santa Maria delle Grazie” Hospital, ASL Napoli 2 Nord, Naples; ²Internal Medicine Ward, Department of Internal Medicine, University of Parma, Italy

Correspondence: Pierpaolo Di Micco, Internal Medicine Ward, “Santa Maria delle Grazie” Hospital, ASL Napoli 2 Nord, Naples, Italy.

E-mail: pdimicco@libero.it

Key words: politic instability, global health, healthcare.

Contributions: all the authors made a substantial intellectual contribution, read and approved the final version of the manuscript, and agreed to be accountable for all aspects of the work.

Conflict of interest: the authors declare that they have no competing interests, and all authors confirm accuracy.

Ethics approval and consent to participate: this manuscript is a policy analysis based on publicly available data and literature. It does not involve human participants, identifiable data, or biological material. Therefore, ethical approval was not required in accordance with institutional and national guidelines.

Informed consent: not applicable.

Patient consent for publication: not applicable.

Availability of data and materials: data available from the corresponding author upon request.

Funding: the authors received no external funding for the preparation of this manuscript.

Dear Editor,

In many high-income countries, the growing influence of politics and public administration over health system governance is fueling public discontent. This problem transcends the divide between public and private healthcare: in public systems, national or regional political decisions often shape strategies for disease prevention and treatment; in private systems, pharmacoeconomic pressures and financial forecasts increasingly influence diagnostic and therapeutic choices.

In the United States, recent reporting in *The Lancet Respiratory Medicine* underscored how political directives and administrative constraints can reverberate through public health. The resurgence of measles, amid federal restrictions that limited communication and weakened public health capacity, illustrates how politicization can hinder outbreak control and erode public trust, especially when transparency is curtailed, and agencies are prevented from communicating promptly and credibly.¹

In Italy, the debate over the composition of national advisory bodies on immunization policy has intensified public scrutiny and undermined confidence in decision-making processes.² Clinicians' concerns have focused less on individual appointees and more on governance: the need for transparent criteria in selecting experts, insulation of technical committees from political influence, and clearer, faster pharmacovigilance pathways for vaccine-related adverse events. Practical lessons from Italy's COVID-19 vaccination campaign, including improved integration between general practitioners, vaccination hubs, and hospitals, remain highly relevant as immunization programmers evolve.

However, political interference extends well beyond pandemic preparedness. The intersection of politics and healthcare increasingly shapes access to innovative therapies, raising profound ethical and equity concerns. A recent *BMJ* report by Kate Bowie highlighted the alarming prospect that the UK list price of tirzepatide (Mounjaro) could nearly triple, prompting urgent questions about which patients will ultimately bear the burden of this internationally "aligned" cost.³

Tirzepatide, a dual glucose-dependent insulintropic polypeptide and glucagon-like peptide-1 receptor agonist, has demonstrated remarkable efficacy in reducing body weight, body mass index, and waist circumference, with many patients achieving ≥ 20 -25% weight loss, far beyond outcomes seen with older agents.⁴ Its safety profile appears favorable, and it holds enormous potential to reduce the cardiovascular and metabolic burden of obesity worldwide. Yet the steep rise in price threatens to limit access to those able to pay, effectively dividing healthcare systems into "rich" and "poor" ones. In some countries, economic decisions made without meaningful input from the clinicians responsible for patient care may lead to certain therapies being deemed "too expensive," regardless of clinical need.

Beyond economics, political interference has also begun to distort the integrity of scientific research itself. As *The Lancet* recently warned, political and ideological pressures have fueled unjustified criticism, downgrading, and even calls for the retraction of peer-reviewed studies for reasons that are political rather than scientific.⁵ Such actions erode both scientific independence and public trust, jeopardizing the credibility of academic medicine.

The inflated international price of tirzepatide may thus represent another step backward in the struggle for equitable care. These dynamics risk undermining physicians' ethical responsibility to ensure equal access to effective therapies, while reinforcing a tiered healthcare structure where innovation becomes a privilege rather than a right. Health, universally recognized as a common good, cannot be protected without safeguarding the autonomy of those directly responsible for it—clinicians, scientists, and the institutions they represent.

Constructively, we propose several cross-context measures to insulate public health and biomedical research from political and economic interference.⁶

First, codify transparent, merit-based criteria for appointments to national advisory groups, and publicly disclose members' expertise, roles, and conflicts of interest.

Second, protect scientific communication and public-facing data from political constraints, enabling agencies to inform the public rapidly and accurately during emergencies.

Third, maintain clear separation between technical decision-making and political oversight, so that evidence, not ideology, guides policy.

Such measures do not pre-empt democratic accountability; rather, they ensure that technically complex, time-sensitive decisions remain grounded in evidence and communicated with clarity by experts selected for competence and integrity. The recent experiences of Italy, the United States, and the United Kingdom remind us that when health governance becomes a proxy for political conflict, the first casualties are public trust and the people's health.

References

1. Furlow B. Vaccine disinformation motivated gunman's attack on US CDC headquarters. *Lancet Respir Med* 2025;S2213-2600(25)00323-6.
2. Paterlini M. Vaccine sceptics appointed to advise Italian government on immunisation. *BMJ* 2025;390:r1710.
3. Bowie K. Mounjaro: UK price set to rise by up to 170% after Trump complaint-will patients have to pay? *BMJ* 2025;390:r1776.
4. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. *N Engl J Med* 2022;387:205-16.
5. Lancet COVID-19 Commissioners, Task Force Chairs, and Commission Secretariat. Lancet COVID-19 commission statement on the occasion of the 75th session of the UN General Assembly. *Lancet* 2020;396:1102-24.
6. Di Micco P, Imbalzano E, Siniscalchi C. Challenges and evolution of the Italian National Health Service: between crisis and reform. *Ital J Med* 2025;19:2100.